secukinumab + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Lupus Nephritis

Conditions

Lupus Nephritis

Trial Timeline

Jul 7, 2020 → Sep 13, 2023

NCT ID

NCT04181762

About secukinumab + Placebo

secukinumab + Placebo is a phase 3 stage product being developed by Novartis for Lupus Nephritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04181762. Target conditions include Lupus Nephritis.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Nephritis were approved

Approved (8) Terminated (7) Active (7)

✅tacrolimusAstellas PharmaApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05722522	Phase 3	Terminated	Aug 10, 2023	Dec 13, 2024	Rotator Cuff Tendinopathy
NCT05758415	Phase 3	Terminated	Aug 2, 2023	Dec 11, 2024	Rotator Cuff Tendinopathy
NCT04737330	Phase 3	Terminated	Nov 29, 2021	May 16, 2023	Thyroid Eye Disease
NCT04732117	Phase 3	Completed	Jul 21, 2021	Feb 14, 2025	Non-radiographic Axial Spondyloarthritis
NCT04181762	Phase 3	Terminated	Jul 7, 2020	Sep 13, 2023	Lupus Nephritis
NCT04156620	Phase 3	Completed	Dec 11, 2019	Dec 20, 2022	Ankylosing Spondylitis
NCT03713632	Phase 3	Completed	Feb 25, 2019	Jul 19, 2022	Hidradenitis Suppurativa
NCT03713619	Phase 3	Completed	Jan 31, 2019	Jul 26, 2022	Hidradenitis Suppurativa
NCT03055494	Approved	Completed	Apr 18, 2017	Feb 26, 2019	Plaque Psoriasis
NCT02896127	Phase 3	Completed	Oct 18, 2016	Mar 19, 2019	Ankylosing Spondyloarthritis
NCT02696031	Phase 3	Completed	Apr 29, 2016	Mar 11, 2021	Non-radiographic Spondyloarthritis
NCT02599129	Phase 2	Terminated	Nov 1, 2015	Nov 1, 2016	Alopecia Areata
NCT02594098	Phase 2	Completed	Nov 1, 2015	Jan 30, 2018	Atopic Dermatitis
NCT02362789	Phase 3	Completed	Jan 4, 2015	Jul 15, 2016	Psoriasis
NCT01989468	Phase 3	Completed	Apr 10, 2014	Mar 28, 2018	Psoriatic Arthritis
NCT02044848	Phase 2	Terminated	Feb 1, 2014	Sep 1, 2014	Type 1 Diabetes Mellitus
NCT01892436	Phase 3	Completed	Sep 30, 2013	Jan 11, 2018	Psoriatic Arthritis
NCT01807520	Phase 3	Completed	Jun 20, 2013	Jan 3, 2017	Moderate to Severe Nail Psoriasis
NCT01537432	Phase 2	Completed	Jan 1, 2012	Dec 1, 2014	Psoriasis, Plaque-type Psoriasis

Competing Products

20 competing products in Lupus Nephritis

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus	Astellas Pharma	Pre-clinical	26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisone	Astellas Pharma	Phase 3	32
tacrolimus	Astellas Pharma	Approved	35
Tacrolimus capsules + Cyclophosphamide injections + Prednisone	Astellas Pharma	Phase 3	40
E6742	Eisai	Phase 1/2	32
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY3471851 + Placebo	Eli Lilly	Phase 1	29
LY3471851 + Placebo	Eli Lilly	Phase 2	35